You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

resistant to prior (neo) adjuvant anti-HER2 therapy.

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • chidamide combined with fulvestrant
  • (no location specified)
Mar 28, 2023

Breast Cancer Trial ([68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
May 22, 2023

Locally Advanced Breast Cancer Trial in Shanghai (pyrotinib)

Recruiting
  • Locally Advanced Breast Cancer
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 11, 2022

HER2-positive Breast Cancer Trial in Nanjing (Pyrotinib)

Recruiting
  • HER2-positive Breast Cancer
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Apr 26, 2023

Breast Cancer Trial in United States (Letrozole, Ribociclib, Placebo)

Active, not recruiting
  • Breast Cancer
  • Little Rock, Arkansas
  • +12 more
Sep 24, 2022

Breast Cancer Trial in Limoges, Villejuif (Anti-aromatase inhibitor)

Not yet recruiting
  • Breast Cancer
  • Anti-aromatase inhibitor
  • Limoges, France
  • +1 more
Jul 25, 2022

Breast Tumors Trial in Mönchengladbach (drug, diagnostic test, procedure)

Active, not recruiting
  • Breast Neoplasms
  • Perjeta Injectable Product
  • +13 more
  • Mönchengladbach, Germany
    Evangelisches Krankenhaus Bethesda Mönchengladbach
Oct 4, 2022

Metastatic Breast Cancer Trial in Springfield, Rochester, Lebanon (17B-estradiol, Letrozole, Anastrozole)

Active, not recruiting
  • Metastatic Breast Cancer
  • Springfield, Massachusetts
  • +2 more
Nov 1, 2022

Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors Trial in Baltimore (Nivolumab, Relatlimab)

Recruiting
  • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
  • MSI-H Tumors
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Mar 14, 2022

Edema, Erythema, Estrogen Receptor Negative Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)

Active, not recruiting
  • Edema
  • +8 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Jan 23, 2023

Locally Advanced Breast Cancer, Metastatic Breast Cancer Trial in Spain (Trastuzumab deruxtecan)

Not yet recruiting
  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Trastuzumab deruxtecan
  • Cádiz, Andalucía, Spain
  • +18 more
Feb 24, 2023

HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 Trial in Norfolk, Omaha (drug,

Active, not recruiting
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Norfolk, Nebraska
  • +2 more
Sep 1, 2021

HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Trastuzumab deruxtecan
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
Aug 7, 2023

Soft Tissue Sarcoma Trial in France (Patients will receive the hypofractionated radiation therapy (30 Gy in 5 fractions) prior

Not yet recruiting
  • Soft Tissue Sarcoma
  • Patients will receive the hypofractionated radiation therapy (30 Gy in 5 fractions) prior to surgery.
  • Patient will undergo surgery before receive the adjuvant hypofractionated radiation therapy (40 Gy in 15 fractions).
  • Bordeaux, France
  • +10 more
Aug 28, 2023

INnovative and Micro-INvasive TEchniques for Early

Recruiting
  • Breast Cancer
  • Liquid biopsy and imaging
  • Aviano, Pordenone, Italy
    Centro di Riferimento Oncologico
Apr 26, 2023

Pancreatic Cancer Trial in Sydney, Wollongong, Melbourne (Durvalumab, Oxaliplatin, Irinotecan)

Recruiting
  • Pancreatic Cancer
  • Sydney, New South Wales, Australia
  • +2 more
Oct 19, 2023

Recurrent Glioblastoma Trial in Brussels (Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV,

Not yet recruiting
  • Recurrent Glioblastoma
  • Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
  • +2 more
  • Brussels, Belgium
    UZ Brussel
Oct 23, 2023

Node-positive Breast Cancer Trial (Targeted axillary lymph node dissection)

Not yet recruiting
  • Node-positive Breast Cancer
  • Targeted axillary lymph node dissection
  • (no location specified)
Jan 6, 2023

Breast Cancer Trial in Duarte, New Haven, Providence (Cohort 1 neo-adjuvant, Cohort 2 neo-adjuvant, Cohort 1 adjuvant)

Completed
Has Results
  • Breast Cancer
  • Cohort 1 neo-adjuvant
  • +3 more
  • Duarte, California
  • +4 more
May 28, 2020

Breast Cancer, Ovarian Cancer, Liposarcoma Trial (PF-07224826, Fulvestrant)

Not yet recruiting
  • Breast Cancer
  • +5 more
  • (no location specified)
Jun 7, 2023

Ovarian Cancer Stage IV, Peritoneal Cancer, Fallopian Tube Cancer Trial in Amsterdam (Carboplatin, Paclitaxel, Pembrolizumab)

Recruiting
  • Ovarian Cancer Stage IV
  • +2 more
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
Mar 21, 2022

HER2-HER3 Dimer in Tumour and Blood Samples From HER2 Positive

Recruiting
  • HER2-positive Breast Cancer
  • Acquisition of blood samples and tumour tissue samples (biopsies)
  • Brighton, United Kingdom
  • +1 more
Nov 9, 2022

Breast Cancer Trial in Helsinki (Pertuzumab, Trastuzumab)

Active, not recruiting
  • Breast Cancer
  • Helsinki, Finland
    Helsinki University Central Hospital
Mar 15, 2022

Breast Cancer Trial in Netherlands (PTC-Pz)

Active, not recruiting
  • Breast Cancer
  • Alkmaar, Netherlands
  • +51 more
Jul 19, 2022